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ABSTRACT 
 
The research that we have conducted has allowed us to discover 
that the amino acids, methionine (Met) and N-acetyl methionine (N-
AcMet), will react in a 1:1 and 1:2 molar ratio with platinum complexes 
containing bulky diamine ligands.  Previous research has allowed us to 
gain a plethora of information on the experimentation and results of 
specific bulky diamine ligands such as N,N,N',N'-
tetramethylethylenediamine and N,N-diethylethylenediamine. In the 
current study, we have investigated the bulky diamine ligand of N,N-
dimethylethylenediamine, or Me2en.  With our focus on the bulk of the 
Me2en ligand, we have been able to synthesize a platinum complex in 
Pt(Me2en)Cl2 and react it with Met and N-AcMet. Through analysis using 
NMR spectroscopy and LC/MS, we have been able to observe the 
formation of a S,O-chelate formation in the reaction of the platinum 
complex with N-AcMet. This implies that a second methionine is not able 
to coordinate to the position that is cis to the bulk.  
 
 
Keywords: Cisplatin, Methionine, Nuclear Magnetic Resonance, Ligand, 
Chelate 
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CHAPTER 1 
 
INTRODUCTION 
 
 As time has progressed, a vast amount of diseases and illnesses 
have become apparent in society.  However, with time, a plethora of 
treatments and scientific advances have made way into the 
pharmaceutical industry to counteract these diseases and illnesses.  One 
of the most significant diseases in the world today is cancer.  There are 
many different forms of cancer that specialize in attacking different 
tissues and organs of the body.  These different forms of cancer tend to 
have such diverse symptoms on the body, with the most significant being 
death.  These devastating symptoms have led to many scientists 
experimenting with a wide array of anticancer treatments ranging from 
new radiation and chemotherapy techniques to development of novel 
anticancer drugs.  These new developments eventually led way to 
research surrounding platinum (II) compounds and their affect on 
suppressing cancer.  This breakthrough in platinum chemistry 
established the foundation for this research project concerning the 
reaction of bulky platinum (II) complex’s with amino acids. 
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 One of the most significant anticancer drugs used today is a 
platinum based drug known as cisplatinum, cisplatin, or cis-
diamminedichloroplatinum.  The discovery of cisplatin and all of its 
anticancer attributes was a great breakthrough in the field of oncology.  
Not only did cisplatin revolutionize how cancer could be treated, but it 
also led to the development and research of other derivatives of platinum 
compounds and their significance on anticancer activity.  Oxaliplatin and 
carboplatin were two platinum compounds discovered from cisplatin that 
have been determined to act as anticancer agents.   
 
 
 
Figure 1. Illustration of cisplatinum, cisplatin, or cis-diamminedichloroplatinum. 
 
 
Cisplatin is an incomparable drug in that it is not complex in 
structure, yet has the ability to target and fight certain cancers in the 
body.  Structurally speaking, cisplatin, or Pt(NH3)2Cl2, consists of two 
ammine ligands and two chloride ligands in ideal biological conditions as 
depicted in Figure 1.  It maintains a square planar geometry1.  Platinum 
(II) tends to have a high affinity for nitrogen and sulfur ligands, which are 
commonly found in proteins and nucleotides in DNA2; this is a result of 
platinum being known as a “soft” acid and bonding strongly as described 
by the Hard Soft Acid Base theory5,6.   This platinum complex can be 
found in two conformations: cis, the commonly used anticancer drug, 
Pt
ClCl
H3N NH3
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and trans, the inactive form5,6.  These features of cisplatin allow it to 
function flawlessly in the body. 
Originally the compound has been known since 1845, but its 
anticancer activity was not discovered until 19701.  Cisplatin, formely 
known as Peyrone’s chloride, was synthesized by Michael Peyrone in 
18451,8.  The drug’s activity was discovered by Dr. Barnett Rosenberg at 
Michigan State University in which he was able to experiment with how 
platinum complexes could lead to inhibition of cell proliferation1,5,6.  
Ironically, Rosenberg was focusing on bacterial growth’s effects from 
electric fields using platinum electrodes; this eventually led to the origin 
of cisplatin1.  Rosenberg was then able to test cisplatin on tumors in 
mice, which showed the effectiveness of the drug1.  Cisplatin was 
eventually approved by the United States Food and Drug Administration 
and became licensed to Bristol-Myers Squibb in 19777.  It is the main 
component in the drug Platinol® and its derivative, carboplatin, is known 
as Paraplatin®7.  The purpose of cisplatin was to be used in 
chemotherapy in order to target ovarian, testicular, stomach, lung, and 
bladder cancers5,6.  The administering of cisplatin for testicular cancer 
treatments has led to a dramatic increase in survival rate from 10% to 
80%7. 
 Not only is cisplatin, and its derivatives, notable for its ability to be 
an ideal treatment for most cancers, but it is also one of a few cancer 
drugs based from inorganic complexes; most cancer drugs used today 
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are complex in structure due to the compilation of many organic 
molecules.  The structure of cisplatin causes it to alter the repair 
mechanism of the cell by binding to the DNA and eventually leading to 
the suppression of cancer cells from proliferating1,2.  Once the drug has 
entered the cell, it undergoes hydrolysis in which a charged platinum 
complex forms while one of the chlorine ligands is displaced due to it 
being replaced by a water molecule1,2.  The platinum complex is 
coordinated to DNA.  The platinum complex eventually coordinates to a 
second nucleotide, resulting because of further hydrolysis and 
displacement of the second chloride ligand1,2.  This newly formed adduct 
eventually leads to a kink in the DNA helix1,2.  The formed complexes 
have a tendency to react with both protein and DNA1,2. 
Cisplatin’s main component, platinum, tends to have a great 
affinity for binding sites on proteins containing sulfur molecules.  Sulfur 
atoms are only available in two kinds of amino acid residues, one being 
cysteine, and the other being of interest, methionine.  The sulfur on the 
methionine contains a slightly partial positive charge and is available as 
a thioether.  The interaction between methionine and cisplatin can lead 
to the formation of monodentate and bidentate compounds.   
 
 
Figure 2. Depiction of the amino acid, methionine. 
NH3
+
OS
O
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The proposed research project focuses on the Pt(Me2en)Cl2 
complex, where the Me2en ligand is N,N-dimethyethylenediamine, and its 
interactions with L-Methionine (Met) and N-Acetyl Methionine (N-AcMet).  
It was noted that Met and N-AcMet reacts in a 1:1 and 1:2 molar ratio 
with platinum complexes containing bulky diamine ligands.   Previous 
research has allowed us to gain a plethora of information on the 
experimentation and results of specific bulky diamine ligands such as 
N,N,N',N'-tetramethylethylenediamine (Me4en) and N,N-
diethylethylenediamine (Et2en)3,4.  The current Me2en ligand does appear 
to have sufficient bulk to prevent coordination of a second Met or N-
AcMet to the coordination position cis to the bulk of the methyl groups.  
The sulfur atom of the first methionine is able to coordinate to the trans 
position, however, a sufficient amount of bulk is still surrounding the cis 
position in relation to the methyl groups on the ligand.  This leads to the 
oxygen of the first methioine coordinating to the cis position and forming 
a S,O- chelate instead of a sulfur atom of a second methionine 
coordinating to that positions.  The displacement of the Me2en ligand 
occurred and the formation of a mono product was detected through 
NMR spectroscopy.   
 
 
 
Figure 3. Structure of Pt(Me2en)Cl2 and Me2en ligand. 
NH2 N
Cl Cl
Pt NH3 N2 
6 
 
This research allows an in-depth perspective of the reaction of bulky 
platinum complexes with L-Methionine and N-Acetyl Methionine and how 
this data can lead to a better understanding of cleavage reactions 
involved in proteins3,4.  
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CHAPTER 2 
 
METHODOLOGY 
 
Synthesis of Pt(Me2en)Cl2: 
In order to properly exhibit the formation of any product through the 
coordination of a peptide, the Pt(Me2en)Cl2 complex needed to be 
synthesized.  Potassium tetrachloroplatinate was dissolved in H2O.  
Dimethylethylenediamine was combined with methanol.  This solution 
was then added drop-wise to the previous solution.  The combined 
solution stirred for 24 hours (developed a “peach” color).  Upon 
completion of stirring, the solution was placed on the rotary evaporator 
in order for the sample to be cooled and a product be precipitated; this 
process yielded a final product of Pt(Me2en)Cl2. 
Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl 
Methionine: 
 
The Pt(Me2en)Cl2 complex needed to be reacted with various proportions 
of amino acids and monitored for periods of times to observe any 
displacement of the Me2en ligand and formation of any product 
complexes.  Approximately 3.5 mg of the platinum complex was dissolved 
in 1.0 mL of deuterium oxide (D2O) and reacted with L-Methionine and 
N-acetyl methionine (2 and 4 mg); these samples were adjusted to a pH 
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of 4.  This allowed us to compare the reactions at a 1:1 and 1:2 molar 
ratio and monitor the samples at various time intervals through NMR 
spectroscopy.   
NMR Spectroscopy: 
The reactions of the platinum complexes with proportions of the peptides 
were analyzed using 1H NMR spectroscopy.  This data was attained on a 
JOEL Eclipse 500MHz NMR instrument. Through NMR spectroscopy and 
analysis, we can determine when there may be a displacement of the 
Me2en ligand, when the major products are forming, and find any 
correlation between the different ratios of the samples. 
LC/MS 
A 5mM concentration of the platinum complex was reacted with a 10mM 
concentration of Met and N-AcMet and then analyzed by liquid 
chromatography/ mass spectrometry.  The data was attained on a Varian 
LC/MS 500 Ion Trap. This instrumentation helps in distinguishing 
various compounds from each other using a mass-to-charge ratio; this is 
useful for this research in detecting any possible chelate formations. 
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CHAPTER 3 
 
RESULTS 
 
Based on the intensity and shift of the peak signals in relation to 
the other signals, we can determine the presence of any product 
complexes, as well as the possible structure/coordination of the product.  
It can be inferred that displacement of the bulky diamine ligand typically 
will only occur when both coordination positions trans to the diamine 
ligand are occupied by sulfur atoms that originated from the amino 
acids. 
However, upon conducting experiments utilizing LC/MS, the 
experiment involving the reaction of the platinum complex with N-AcMet 
suggested that a sulfur atom coordinated to the trans position in relation 
to the methyl groups on the ligand, and the oxygen atom on the same 
methionine coordinated to the cis position—this formed a S,O chelate.  
This was determined from the LC/MS by a peak at 473.3 mass-to-charge 
ratio.   
Previous studies with Pt(Me4en)(NO3)2 complexes have indicated 
that only one Met or N-AcMet could possibly coordinate because of steric 
clashes3,4.  Together, these results have been able to suggest that two 
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methyl groups on one amine nitrogen are sufficient to prevent 
coordination of a sulfur atom from a second methionine. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structure of Pt(Me2en)(NAcMet-S,O). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H2N N 
Pt 
S O 
NH 
O 
O 
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Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl Methionine 
[1:1 ratio]: 
 
Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with 
4mg of L-Methionine.  This reaction was observed by NMR analysis and 
data was collected at time intervals of 1, 4, and 24 hours. 
 
Figure 5. Reaction of Methionine and Pt(Me2en)Cl2 at a 1:1 molar ratio; monitored at (a) 
1 hr (b) 4 hrs (c) 24 hrs. 
3.4 2.4 
a. 
b. 
c. 
Unreacted 
Methionine 
Mono 
Product 
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Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with 
4mg of N-Acetyl Methionine.  This reaction was observed by NMR 
analysis and data was collected at time intervals of 1, 4, and 24 hours. 
 
 
Figure 6. Reaction of N-Acetyl Methionine with Pt(Me2en)Cl2 at a 1:1 molar ratio; 
monitored at (a) 1 hr (b) 4 hrs (c) 24 hrs. 
a. 
b. 
3.4 2.4 
c. 
Unreacted 
N-Acetyl 
Methionine 
Mono 
Product 
Me2en 
ligand 
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Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl Methionine 
[1:2 ratio]: 
 
Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with 
2mg of L-Methionine.  This reaction was observed by NMR analysis and 
data was collected at time intervals of 1, 4, and 24 hours. 
 
Figure 7. Reaction of L-Methionine with Pt(Me2en)Cl2 at 2:1 ratio; monitored at (a) 1hr 
(b) 4hrs (c) 24 hrs. 
3.4 2.4 
a. 
b. 
c. 
Unreacted 
Methionine 
Mono 
Product 
Me2en 
ligand 
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Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with 
2mg of N-Acetyl Methionine.  This reaction was observed by NMR 
analysis and data was collected at time intervals of 1, 4, and 24 hours. 
 
Figure 8. Reaction of N-Acetyl Methionine with Pt(Me2en)Cl2 at a 2:1 ratio; monitored at 
(a)1hr (b) 4hrs (c) 24 hrs. 
 
3.4 2.4 
a. 
b. 
c. 
Me2en 
ligand 
Unreacted 
N-Acetyl 
Methionine 
Mono 
Product 
 Peak signals at ~3.0ppm and ~3.4ppm correspond
Me2en ligand.  This is attained 
methionine. 
Reaction of 5mM Pt(Me
     Figure 9. Mass spectrometry data of
 
Pt(Me
15 
 to displacement of the 
through the coordination of the 
2en)Cl2 with 10mM N-AcMet (LC/MS):
 N-Acetyl Methionine with Pt(Me
 
 
 
 
 
 
 
 
2en)(NAcMet-S,O) 
2en)Cl2 . 
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CHAPTER 4 
 
DISCUSSION 
 
It was suspected that due to the sufficient bulk of the Me2en 
ligand, there would not be coordination of a second L-Methionine or N-
Acetyl Methionine to the platinum complex.  Past research has shown 
that various bulky ligands, such as Et2en and Me4en, do not allow the 
sulfur atom of a second methionine to coordinate to the platinum 
complex3-5.  The research surrounding these other bulky ligands were 
able to conclude that only one methionine would coordinate to the 
platinum complexes and result in the formation of a S,O-chelate.  Hence, 
the objective of this research project was to determine the significance of 
bulkiness of this ligand and how the bulk on the platinum complex 
relates to the binding of methionine’s found in proteins in the body.  This 
research project, implementing NMR spectroscopy and LC/MS,  allowed 
the retrieval of significant data leading towards the probability of the 
formation of a S,O-chelate. 
Past research has proven that the sulfur atom of methionine will 
react rapidly with the platinum.  So, it could be inferred that the sulfur 
atom would react at either the cis or trans coordination positions relative 
17 
 
to the nitrogen atom containing the two methyl groups.  The sulfur atom 
has the greatest probability of coordinating to the trans position.  The 
bulk of the Me2en ligand, and specifically the bulky nitrogen atom, are 
showing that the sulfur cannot be in the cis position, and leads to the 
formation of [Pt(Me2en)(N-AcMet-S,O)].  This chelate formation was 
verified by a peak at 473.3 mass-to-charge ratio under LC/MS analysis, 
as well as a doublet of doublets formation at ~5.4ppm through NMR 
spectroscopy.  Research performed on the Et2en and Me4en ligand 
reported that the sulfur atom from methionine will coordinate to the 
trans position relative to the bulky nitrogen atom as well.  However, that 
research also reported that the bulk of those ligands caused no 
coordination of another sulfur atom from methionine at the cis position.  
This research on the Me2en ligand shows that this bulk still allows 
coordination of the carboxyl oxygen of N-Acetyl Methionine to the cis 
position, eventually resulting in a S,O-chelate.  It is also to be noted that 
previous studies showed the formation of S,O-chelates involving the 
coordination of amino acids to platinum complexes. 
The present study allowed the utilization of a platinum complex 
containing a non-C2-symmetrical Me2en ligand to determine if excessive 
bulk on one of the two nitrogens of the diamine ligand could inhibit 
coordination of the second methionine to the platinum complex and/or 
greatly affect the type of chelate that would form. This research helps to 
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understand to the basis of cleavage reactions found in proteins during 
the reaction of platinum complexes with methionine. 
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CHAPTER 5 
 
FUTURE WORK 
 
Further research will allow us to focus on the characterization of 
the products using NMR spectroscopy, high pressure liquid 
chromatography (HPLC), and mass spectrometry.  Currently, more 
analysis is being done using 2D NMR and various kinetic NMR 
experiments.  It is also essential to characterize the products formed in 
the reactions of Pt(Me2en)Cl2 with 5’-GMP (guanosine monophoshpate).  
Lastly, focus on the rates of reactions and molecular mechanics of 
Pt(Me2en)Cl2 with methionine and guanine targets is crucial in the 
continuation of this research. 
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